Progression of Parkinson's disease is associated with gut dysbiosis: Two-year follow-up study
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
BACKGROUND: We previously reported gut dysbiosis in patients with Parkinson's disease (PD). OBJECTIVE: The aim of this study is to examine whether gut dysbiosis correlates with the progression of PD. METHODS: We examined changes in gut microbiota and demographic features in 2 years in 36 PD patients. RESULTS: A change of total UPDRS scores in 2 years was predicted by the counts of Bifidobacterium and Atopobium cluster at year 0 with a correlation coefficient of 0.52. Correlation analysis additionally revealed that low counts of Bifidobacterium and Bacteroides fragilis at year 0 were associated with worsening of UPDRS I scores in 2 years. In addition, low counts of Bifidobacterium at year 0 were associated with worsening of hallucinations/delusions in 2 years. Similarly, low counts of B. fragilis at year 0 were associated with worsening of motivation/initiative in 2 years. The patients were evenly divided into the deteriorated and stable groups based on the degree of worsening of total UPDRS scores. The deteriorated group had lower counts of Bifidobacterium, B. fragilis, and Clostridium leptium than the stable group at year 0 but not at year 2, suggesting that the deteriorated group may demonstrate accelerated lowering of these bacteria at year 0. CONCLUSIONS: The total counts of intestinal bacterial decrease in the course of PD progression. Temporal profiles of lowering of bacterial counts are likely to be different from bacteria to bacteria, and also between the deteriorating and stable groups, which may be able to be exploited to differentiate patients with rapidly and slowly progressive PD pathology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Minato et al. 57 investigated the relationship between intestinal disorders and disease progression through a 2-year follow-up of patients with Parkinson's disease and found that the decreased abundance of Bifidobacterium and Bacteroides fragilis was related to the deterioration of the Unified Parkinson's Disease Rating Scale (UPDRS)-I score”
From The role of gut dysbiosis in Parkinson’s disease: mechanistic insights and therapeutic options (2021) · cites this paper as [57]
The cited source says what the claim attributes to it.
In the citing paper
“suggesting that the gut microbiota may be seriously influenced by disease progression.57”
From The role of gut dysbiosis in Parkinson’s disease: mechanistic insights and therapeutic options (2021) · cites this paper as [57]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Parkinsonism: onset, progression, and mortality
Hoehn, M. M., & Yahr, M. D. (1967) · Neurology · doi:10.1212/wnl.17.5.427 · Cited by 12,107
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
(1996) · Institutional Research Information System University of Turin (University of Turin) · doi:10.1111/j · Cited by 5,486
Overdependence on degraded gist memory in Alzheimer's disease.
Gallo, D. A., Shahid, K. R., Olson, M. A., Solomon, T. M., Schacter, D. L., & Budson, A. E. (2006) · Neuropsychology · doi:10.1037/0894-4105.20.6.625 · Cited by 4,732
The FAB: A frontal assessment battery at bedside
Dubois, B., Slachevsky, A., Litvan, I., & Pillon, B. (2000) · Neurology · doi:10.1212/wnl.55.11.1621 · Cited by 3,913
Gut Microbiota from Twins Discordant for Obesity Modulate Metabolism in Mice
Ridaura, V. K., Faith, J. J., Rey, F. E., Cheng, J., Duncan, A. E., Kau, A. L., Griffin, N. W., Lombard, V., Henrissat, B., Bain, J. R., et al. (2013) · Science · doi:10.1126/science.1241214 · Cited by 3,788
Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease
Sampson, T. R., Debelius, J. W., Thron, T., Janssen, S., Shastri, G. G., Ilhan, Z. E., Challis, C., Schretter, C. E., Rocha, S., Gradinaru, V., et al. (2016) · Cell · doi:10.1016/j.cell.2016.11.018 · Cited by 3,622
Atopic Dermatitis: Global Epidemiology and Risk Factors
Nutten, S. (2015) · Annals of Nutrition and Metabolism · doi:10.1159/000370220 · Cited by 3,055
Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030
Dorsey, E. R., Constantinescu, R., Thompson, J. P., Biglan, K. M., Holloway, R. G., Kieburtz, K., Marshall, F. J., Ravina, B. M., Schifitto, G., Siderowf, A., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000247740.47667.03 · Cited by 2,472
The prevalence of Parkinson's disease: a systematic review and meta-analysis
Pringsheim, T., Jette, N., Frolkis, A., & Steeves, T. D. L. (2014) · Movement Disorders · doi:10.1002/mds.25945 · Cited by 2,188
Cited by
Microbiota in health and diseases
Hou, K., Wu, Z.-X., Chen, X.-Y., Wang, J.-Q., Zhang, D., Xiao, C., Zhu, D., Koya, J. B., Wei, L., Li, J., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00974-4 · Cited by 3,171
Discovery and inhibition of an interspecies gut bacterial pathway for Levodopa metabolism
Maini Rekdal, V., Bess, E. N., Bisanz, J. E., Turnbaugh, P. J., & Balskus, E. P. (2019) · Science · doi:10.1126/science.aau6323 · Cited by 753
Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism
Barichella, M., Severgnini, M., Cilia, R., Cassani, E., Bolliri, C., Caronni, S., Ferri, V., Cancello, R., Ceccarani, C., Faierman, S., et al. (2019) · Movement Disorders · doi:10.1002/mds.27581 · Cited by 393
“Consistently with previous studies (Supplementary Table 1), we observed a decrease in taxa belonging to Firmicutes pylum, such as the Lachnospiraceae family and other genera (eg, Roseburia)(10,13,15,20,21,23) and an increase in Verrucomicrobia,(9,10,13,15,19) Proteobacteria,(10,13,21,23,50) Christensenellaceae,(15,20)…”
ResultInfluentialThe microbiome–gut–brain axis in Parkinson disease — from basic research to the clinic
Tan, A. H., Lim, S. Y., & Lang, A. E. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00681-2 · Cited by 392
Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression
Aho, V. T. E., Pereira, P. A. B., Voutilainen, S., Paulin, L., Pekkonen, E., Auvinen, P., & Scheperjans, F. (2019) · eBioMedicine · doi:10.1016/j.ebiom.2019.05.064 · Cited by 361
“One previous publication on gutmicrobiota and PD progression, also with a 2-year follow-up period, found that stable and deteriorated patients had similar microbiota at each timepoint, although Bifidobacterium was less abundant in deteriorated patients at baseline [17].”
BackgroundMethodResultInfluentialChanges of colonic bacterial composition in Parkinson's disease and other neurodegenerative diseases
Gerhardt, S., & Mohajeri, M. H. (2018) · Nutrients · doi:10.3390/nu10060708 · Cited by 298
The role of gut dysbiosis in Parkinson’s disease: mechanistic insights and therapeutic options
Wang, Q., Luo, Y., Ray Chaudhuri, K., Reynolds, R., Tan, E.-K., & Pettersson, S. (2021) · Brain · doi:10.1093/brain/awab156 · Cited by 281
Pellegrini, C., Antonioli, L., Colucci, R., Blandizzi, C., & Fornai, M. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1856-5 · Cited by 270
“, anxiety, depression, learning and memory) [26, 55, 60, 97].”
Yuille, S., Reichardt, N., Panda, S., Dunbar, H., & Mulder, I. E. (2018) · PLOS ONE · doi:10.1371/journal.pone.0201073 · Cited by 257
The Role of Lipids in Parkinson’s Disease
Xicoy, H., Wieringa, B., & Martens, G. J. M. (2019) · Cells · doi:10.3390/cells8010027 · Cited by 250
The Microbiome as a Modifier of Neurodegenerative Disease Risk
Fang, P., Kazmi, S. A., Jameson, K. G., & Hsiao, E. Y. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.06.008 · Cited by 226
“Interestingly, longitudinal studies assessing the temporal dynamics of microbiota composition in PD patients indicate that microbial changes remain relatively stable over years following the onset of PD symptoms (Aho et al., 2019; Minato et al., 2017).”
BackgroundThe Association Between the Gut Microbiota and Parkinson’s Disease, a Meta-Analysis
Shen, T., Yue, Y., He, T., Huang, C., Qu, B., Lv, W., & Lai, H.-Y. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.636545 · Cited by 219
“A 2-year follow-up study indicated that the total counts of gut microbiota decreased during the course of PD progression and differed between deteriorating and stable PD groups, which may be used as a diagnostic tool for monitoring the progression of PD (Minato et al., 2017).”
MethodSrivastav, S., Neupane, S., Bhurtel, S., Katila, N., Maharjan, S., Choi, H., Hong, J. T., & Choi, D.-Y. (2019) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2019.03.021 · Cited by 212
Gut bacterial profiles in Parkinson's disease: A systematic review
Li, Z., Liang, H., Hu, Y., Lu, L., Zheng, C., Fan, Y., Wu, B., Zou, T., Luo, X., Zhang, X., et al. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13990 · Cited by 206
Probiotic Bacillus subtilis protects against α-synuclein aggregation in C. elegans
Goya, M. E., Xue, F., Sampedro-Torres-Quevedo, C., Arnaouteli, S., Riquelme-Dominguez, L., Romanowski, A., Brydon, J., Ball, K. L., Stanley-Wall, N. R., & Doitsidou, M. (2020) · Cell Reports · doi:10.1016/j.celrep.2019.12.078 · Cited by 205
“Previous studies suggest that the presence of distinct groups of bacteria in the gut microbiome modulate PD pathology (Minato et al., 2017; Sampson et al., 2016; Scheperjans et al., 2015).”
BackgroundChidambaram, S. B., Essa, M. M., Rathipriya, A. G., Bishir, M., Ray, B., Mahalakshmi, A. M., Tousif, A. H., Sakharkar, M. K., Kashyap, R. S., Friedland, R. P., et al. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107988 · Cited by 204
Hazan, S. (2020) · Journal of International Medical Research · doi:10.1177/0300060520925930 · Cited by 200
Parkinson’s disease and gut microbiota: from clinical to mechanistic and therapeutic studies
Zhang, X., Tang, B., & Guo, J. (2023) · Translational Neurodegeneration · doi:10.1186/s40035-023-00392-8 · Cited by 187
“Low counts of Bacteroides fragilis are associated with deterioration of motivation/ activeness, whereas Bifidobacterium is correlated with hallucinations/delusions [113].”
BackgroundHsieh, T.-H., Kuo, C.-W., Hsieh, K.-H., Shieh, M.-J., Peng, C.-W., Chen, Y.-C., Chang, Y.-L., Huang, Y.-Z., Chen, C.-C., Chang, P.-K., et al. (2020) · Brain Sciences · doi:10.3390/brainsci10040206 · Cited by 174
“Furthermore, the abundance of Lachnospiraceae and Enterobacteriaceae are related to disease severity, disease progression, and motor impairment in PD [53,54].”
BackgroundSnigdha, S., Ha, K., Tsai, P., Dinan, T. G., Bartos, J. D., & Shahid, M. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107978 · Cited by 171
Parkinson’s Disease and the Gastrointestinal Microbiome
Lubomski, M., Tan, A. H., Lim, S.-Y., Holmes, A. J., Davis, R. L., & Sue, C. M. (2020) · Journal of Neurology · doi:10.1007/s00415-019-09320-1 · Cited by 172
“Consequently, dysbiosis of the GM portrays an interesting lead to explore the pathogenesis of PD [12, 13] and presents as a novel diagnostic and therapeutic target [14].”
BackgroundMethodInfluentialBoertien, J. M., Pereira, P. A. B., Aho, V. T. E., & Scheperjans, F. (2019) · Journal of Parkinson’s Disease · doi:10.3233/jpd-191711 · Cited by 170
“To date, two longitudinal follow273 up microbiome studies in PD have been performed 274 [30, 38].”
BackgroundThe Role of the Gut Microbiota in the Pathogenesis of Parkinson's Disease
Yang, D., Zhao, D., Ali Shah, S. Z., Wu, W., Lai, M., Zhang, X., Li, J., Guan, Z., Zhao, H., Li, W., et al. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.01155 · Cited by 162
Fecal microbiota transplantation beyond Clostridioides difficile infections
Wortelboer, K., Nieuwdorp, M., & Herrema, H. (2019) · eBioMedicine · doi:10.1016/j.ebiom.2019.05.066 · Cited by 163
“An observational study found a decrease in total count of gut microbiota during PD progression and changes in gut microbiota could be correlated with a rapid or slow disease progression [79].”
BackgroundDuPont, H. L., Suescun, J., Jiang, Z.-D., Brown, E. L., Essigmann, H. T., Alexander, A. S., DuPont, A. W., Iqbal, T., Utay, N. S., Newmark, M., et al. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1104759 · Cited by 162
Peterson, C. T. (2020) · Journal of Evidence-Based Integrative Medicine · doi:10.1177/2515690x20957225 · Cited by 160
Liao, J.-F., Cheng, Y.-F., You, S.-T., Kuo, W.-C., Huang, C.-W., Chiou, J.-J., Hsu, C.-C., Hsieh-Li, H.-M., Wang, S., & Tsai, Y.-C. (2020) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.07.036 · Cited by 159
“…in the fluctuations of specific gut bacterial populations between MPTP rodent studies and clinical studies highlight the gut dysbiosis caused by changes in bowel habits in the early stages of PD (Keshavarzian et al., 2015; Minato et al., 2017; Pietrucci et al., 2019; Unger et al., 2016).”
BackgroundParkinson’s Disease and Gut Microbiota
Hirayama, M., & Ohno, K. (2021) · Annals of Nutrition and Metabolism · doi:10.1159/000518147 · Cited by 158
Self-citationLi, Y., Peng, Y., Shen, Y., Zhang, Y., Liu, L., & Yang, X. (2023) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2022.2076064 · Cited by 156
“The level of Prevotellaceae was considered to a biomarker of neurodegenerative disease severity, and its abundance decreased as the disease progress (Minato et al. 2017).”
BackgroundProbiotics for Parkinson’s Disease
Gazerani, P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174121 · Cited by 151
Dutta, S. K., Verma, S., Jain, V., Surapaneni, B. K., Vinayek, R., Phillips, L., & Nair, P. P. (2019) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm19044 · Cited by 149
“Recent studies conducted in Japan suggest the role of certain bacteria in the worsening of PD and associated symptoms.(10) Low counts of B.”
BackgroundMethodResultInfluentialDiet in Parkinson’s Disease: Critical Role for the Microbiome
Jackson, A., Forsyth, C. B., Shaikh, M., Voigt, R. M., Engen, P. A., Ramirez, V., & Keshavarzian, A. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.01245 · Cited by 145
Probiotics may have beneficial effects in parkinson’s disease: In vitro evidence
Magistrelli, L., Amoruso, A., Mogna, L., Graziano, T., Cantello, R., Pane, M., & Comi, C. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00969 · Cited by 144
“In addition, a direct correlation between gut bacterial count and disease progression was found in PD patients (14).”
BackgroundGut Metagenomics-Derived Genes as Potential Biomarkers of Parkinson’s Disease
Qian, Y., Yang, X., Xu, S., Huang, P., Li, B., Du, J., He, Y., Su, B., Xu, L.-M., Wang, L., et al. (2020) · Brain · doi:10.1093/brain/awaa201 · Cited by 139
The Link between Gut Dysbiosis and Neuroinflammation in Parkinson’s Disease
Baizabal-Carvallo, J. F., & Alonso-Juarez, M. (2020) · Neuroscience · doi:10.1016/j.neuroscience.2020.02.030 · Cited by 130
Spichak, S., Bastiaanssen, T. F. S., Berding, K., Vlckova, K., Clarke, G., Dinan, T. G., & Cryan, J. F. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.02.044 · Cited by 127
The gut-brain vascular axis in neuroinflammation
Carloni, S., & Rescigno, M. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101802 · Cited by 139
Implications of Diet and The Gut Microbiome in Neuroinflammatory and Neurodegenerative Diseases
Hirschberg, S., Gisevius, B., Duscha, A., & Haghikia, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20123109 · Cited by 117
“For instance, in Parkinson ́s disease (PD), the abundance of the genera Prevotellaceae—known as SCFA-producers—was shown to be reduced [78].”
BackgroundThe Gut-Brain Axis: Two Ways Signaling in Parkinson’s Disease
Dogra, N., Mani, R. J., & Katare, D. P. (2021) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-021-01066-7 · Cited by 133
Gut Vibes in Parkinson's Disease: The Microbiota‐Gut‐Brain Axis
Bullich, C., Keshavarzian, A., Garssen, J., Kraneveld, A., & Perez‐Pardo, P. (2019) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.12840 · Cited by 114
“It should be noted that these studies were conducted in different parts of the United States,52,55 Europe (including Western51,54,57,58,60,63 and Eastern Europe56), and Asia.53,59,61,62 All studies found abnormal microbiota composition in PD compared to controls.”
BackgroundMethodResultInfluentialManagement of Pain in Parkinson’s Disease
Buhmann, C., Kassubek, J., & Jost, W. H. (2020) · Journal of Parkinson s Disease · doi:10.3233/jpd-202069 · Cited by 133
The gut microbiome in Parkinson's disease: A culprit or a bystander?
(2020) · Progress in Brain Research · doi:10.1016/bs.pbr.2020.01.004 · Cited by 103
The pandemic exposes human nature: 10 evolutionary insights
Seitz, B. M., Aktipis, A., Buss, D. M., Alcock, J., Bloom, P. A., Gelfand, M. J., Harris, S., Lieberman, D., Natterson-Horowitz, B., Pinker, S. A., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2009787117 · Cited by 109
Gut bacterial composition in a mouse model of Parkinson’s disease
Perez-Pardo, P., Dodiya, H. B., Engen, P. A., Naqib, A., Forsyth, C. B., Green, S. J., Garssen, J., Keshavarzian, A., & Kraneveld, A. D. (2018) · Beneficial Microbes · doi:10.3920/bm2017.0202 · Cited by 102
“A deficit of Bifidobacterium in subjects with Parkinson’s disease might be a predictive factor for symptom worsening in a two-year period (Minato et al., 2017).”
InfluentialPotential roles of gut microbiota and microbial metabolites in Parkinson’s disease
Zheng, S.-Y., Li, H.-X., Xu, R.-C., Miao, W.-T., Dai, M.-Y., Ding, S.-T., & Liu, H.-D. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101347 · Cited by 101
Dumitrescu, L., Marta, D., Dănău, A., Lefter, A., Tulbă, D., Cozma, L., Manole, E., Gherghiceanu, M., Ceafalan, L. C., & Popescu, B. O. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.689723 · Cited by 100
“In people with chronic diarrhea and other symptoms suggestive of IBD, fecal calprotectin below 50 mcg/g excludes clinically relevant intestinal inflammation, while levels above 250 mcg/g are highly specific (Diamanti et al., 2010; Jensen et al., 2011; Dhaliwal et al., 2015; Moein et al., 2017).”
BackgroundProbiotics in Treatment of Viral Respiratory Infections and Neuroinflammatory Disorders
Shahbazi, R., Yasavoli‐Sharahi, H., Alsadi, N., Ismail, N., & Matar, C. (2020) · Molecules · doi:10.3390/molecules25214891 · Cited by 115
Of microbes and minds: A narrative review on the second brain aging
Calvani, R., Picca, A., Lo Monaco, M. R., Landi, F., Bernabei, R., & Marzetti, E. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00053 · Cited by 92
“Finally, the total abundance of intestinal bacterial was found to decrease during PD progression, with a low count of Bifidobacterium associated with worsening of PD symptoms (134).”
BackgroundOral Dysbiosis and Inflammation in Parkinson’s Disease
Fleury, V., Zekeridou, A., Lazarević, V., Gaïa, N., Giannopoulou, C., Genton, L., Cancela, J., Girard, M., Goldstein, R., Bally, J. F., et al. (2021) · Journal of Parkinson s Disease · doi:10.3233/jpd-202459 · Cited by 107
Suzuki, A., Ito, M., Hamaguchi, T., Mori, H., Takeda, Y., Baba, R., Watanabe, T., Kurokawa, K., Asakawa, S., Hirayama, M., et al. (2018) · PLOS ONE · doi:10.1371/journal.pone.0208313 · Cited by 88
Self-citationGut Inflammation in Association With Pathogenesis of Parkinson’s Disease
Chen, Q.-Q., Haikal, C., Li, W., & Li, J.-Y. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00218 · Cited by 89
Varesi, A., Campagnoli, L. I. M., Fahmideh, F., Pierella, E., Romeo, M., Ricevuti, G., Nicoletta, M., Chirumbolo, S., & Pascale, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012289 · Cited by 88
“Their counterintuitive enrichment in stools from PD patients, reported in most studies [41,53,54,68,71,72,79] with few exceptions [78,89,90], could represent a compensatory mechanism to restore intestinal homeostasis [41].”
BackgroundGut-first Parkinson’s disease is encoded by gut dysbiome
Muñoz, M., Candeias, E., Melo-Marques, I., Esteves, A. R., Maranha, A., Magalhães, J. D., Carneiro, D. R., Sant’Anna, M., Pereira-Santos, A. R., Abreu, A. E., et al. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00766-0 · Cited by 97
Kip, E., & Parr‐Brownlie, L. C. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101618 · Cited by 97
O’Donovan, S. M., Crowley, E. K., Brown, J. R. ‐., O’Sullivan, O., O’Leary, O. F., Timmons, S., Nolan, Y. M., Clarke, D. J., Hyland, N. P., Joyce, S. A., et al. (2020) · Neurogastroenterology & Motility · doi:10.1111/nmo.13726 · Cited by 86
Lombardi, V. C., Meirleir, K. L. D., Subramanian, K., Nourani, S. M., Dagda, R. K., Delaney, S. L., & Palotás, A. (2018) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2018.04.004 · Cited by 101
“Notably, alterations in the gutmicrobiome in PD cases are significantly associated with worsened PD-associated symptoms [68].”
Microbiome changes: an indicator of Parkinson’s disease?
Haikal, C., Chen, Q.-Q., & Li, J.-Y. (2019) · Translational Neurodegeneration · doi:10.1186/s40035-019-0175-7 · Cited by 83
Impact of Gut Dysbiosis on Neurohormonal Pathways in Chronic Kidney Disease
Jazani, N. H., Savoj, J., Lustgarten, M. S., Lau, W. L., & Vaziri, N. D. (2019) · Diseases · doi:10.3390/diseases7010021 · Cited by 90
“Changes in the composition and function of the microbiota, which is referred to as dysbiosis, has been reported in numerous illnesses including obesity [49], diabetes mellitus [45,50], asthma [45], non-alcoholic fatty liver disease [51], heart failure [45], Parkinson’s disease [52], inflammatory bowel disease [53], CV…”
BackgroundRe-thinking the Etiological Framework of Neurodegeneration
Castillo, X., Castro-Obregón, S., Gutiérrez-Becker, B., Gutiérrez-Ospina, G., Karalis, N., Khalil, A. A., Lopez-Noguerola, J. S., Rodríguez, L. L., Martínez-Martínez, E., Perez-Cruz, C., et al. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00728 · Cited by 79
“Gut Microbiota Alterations in Neurodegenerative Diseases Recent reports concomitantly demonstrate a gut dysbiosis in PD (Minato et al., 2017; Wu et al., 2017), ALS, and AD patients (Cattaneo et al.”
BackgroundPadhi, P., Worth, C., Zenitsky, G. D., Jin, H., Sambamurti, K., Anantharam, V., Kanthasamy, A., & Kanthasamy, A. G. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.836605 · Cited by 87
Upregulation of α-synuclein following immune activation: Possible trigger of Parkinson's disease
Kasen, A., Houck, C., Burmeister, A. R., Sha, Q., Brundin, L., & Brundin, P. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105654 · Cited by 78
“Studies have demonstrated dysbiosis in PD patients (Huang et al., 2021; Nishiwaki et al., 2020), which was associated with disease progression (Minato et al., 2017).”
BackgroundPerez Visñuk, D., Savoy de Giori, G., LeBlanc, J. G., & de Moreno de LeBlanc, A. (2020) · Nutrition · doi:10.1016/j.nut.2020.110995 · Cited by 76
Alzheimer’s Disease and Diabetes: Role of Diet, Microbiota and Inflammation in Preclinical Models
Carranza-Naval, M. J., Vargas-Soria, M., Hierro‐Bujalance, C., Baena‐Nieto, G., García-Alloza, M., Infante‐Garcia, C., & del Marco, À. (2021) · Biomolecules · doi:10.3390/biom11020262 · Cited by 88
“On the other hand, the brain-gut-microbiota axis also relates microbiota with brain pathologies like AD and Parkinson’s disease [90,91].”
BackgroundBile acid receptors and signaling crosstalk in the liver, gut and brain
Ferrell, J. M., & Chiang, J. Y. L. (2021) · Liver Research · doi:10.1016/j.livres.2021.07.002 · Cited by 77
dos Santos, J. C. C., Oliveira, L. F., Noleto, F. M., Gusmão, C. T. P., Brito, G. A. D. C., & Viana, G. S. D. B. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.373673 · Cited by 76
“Moreover, a preliminary study suggests that the worsening of motor and nonmotor symptoms may be associated with a rapid decrease in gut microbiota variability (Minato et al., 2017).”
BackgroundNew hope for Parkinson’s disease treatment: Targeting gut microbiota
Fan, H., Sheng, S., & Zhang, F. (2022) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13916 · Cited by 66
Parkinson’s Disease and the Gut: Symptoms, Nutrition, and Microbiota
Yemula, N., Dietrich, C. M., Dostal, V., & Hornberger, M. (2021) · Journal of Parkinson s Disease · doi:10.3233/jpd-212707 · Cited by 75
Yadav, S., Dwivedi, A., Tripathi, A., & Tripathi, A. K. (2022) · Nutrition Research · doi:10.1016/j.nutres.2022.07.007 · Cited by 67
Meta-analysis of shotgun sequencing of gut microbiota in Parkinson’s disease
Nishiwaki, H., Ueyama, J., Ito, M., Hamaguchi, T., Takimoto, K., Maeda, T., Kashihara, K., Tsuboi, Y., Mori, H., Kurokawa, K., et al. (2024) · npj Parkinson s Disease · doi:10.1038/s41531-024-00724-z · Cited by 86
Self-citationLubomski, M., Xu, X., Holmes, A. J., Muller, S., Yang, J. Y. H., Davis, R. L., & Sue, C. M. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.875261 · Cited by 59
Metagenomics of the Gut Microbiome in Parkinson's Disease: Prodromal Changes
Palacios, N., Wilkinson, J., Bjornevik, K., Schwarzschild, M. A., McIver, L., Ascherio, A., & Huttenhower, C. (2023) · Annals of Neurology · doi:10.1002/ana.26719 · Cited by 59
Kashtanova, D. A., Tkacheva, O. N., Strazhesko, I. D., Dudinskaya, Е. N., Kotovskaya, Y. V., Popenko, A., Tyakht, A., & Alexeev, D. G. (2019) · Healthy ageing and longevity · doi:10.1007/978-3-030-24970-0_17 · Cited by 59
Target Dysbiosis of Gut Microbes as a Future Therapeutic Manipulation in Alzheimer’s Disease
Zhu, F., Li, C., Chu, F., Tian, X., & Zhu, J. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.544235 · Cited by 57
Gut microbiota in dementia with Lewy bodies
Nishiwaki, H., Ueyama, J., Kashihara, K., Ito, M., Hamaguchi, T., Maeda, T., Tsuboi, Y., Katsuno, M., Hirayama, M., & Ohno, K. (2022) · npj Parkinson s Disease · doi:10.1038/s41531-022-00428-2 · Cited by 70
Self-citationAl-Khafaji, A. H., Jepsen, S. D., Christensen, K. R., & Vigsnæs, L. K. (2020) · Journal of Functional Foods · doi:10.1016/j.jff.2020.104176 · Cited by 67
Ceppa, F., Izzo, L., Sardelli, L., Raimondi, I., Tunesi, M., Albani, D., & Giordano, C. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00297 · Cited by 60
The role of nutrition on Parkinson’s disease: a systematic review
Bianchi, V. E., Rizzi, L., & Somaa, F. A. (2022) · Nutritional Neuroscience · doi:10.1080/1028415x.2022.2073107 · Cited by 66
Role and Mechanism of Vitamin A Metabolism in the Pathophysiology of Parkinson’s Disease
Marie, A., Darricau, M., Touyarot, K., Parr‐Brownlie, L. C., & Bosch‐Bouju, C. (2021) · Journal of Parkinson s Disease · doi:10.3233/jpd-212671 · Cited by 70
Lee, Y. Z., Cheng, S.-H., Chang, M.-Y., Lin, Y., Wu, C.-C., & Tsai, Y.-C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076794 · Cited by 63
“An increase in the abundances of Bifidobacterium, Ruminiclostridium_6, Adlercreutzia, ASF356, and Acetatifactor, and a decrease in those of Ruminococcaceae_UCG_014, Bacteroides, and Alistipes were correlated with an improvement in motor deficits of PD-like mice.”
BackgroundInfluentialUrolithins: Potential Biomarkers of Gut Dysbiosis and Disease Stage in Parkinson’s Patients
Romo-Vaquero, M., Fernández-Villalba, E., Gil-Martinez, A.-L., Cuenca-Bermejo, L., Espín, J. C., Herrero, M. T., & Selma, M. V. (2022) · Food & Function · doi:10.1039/d2fo00552b · Cited by 54
Microbiota of the gastrointestinal tract: Friend or foe?
Senchukova, M. A. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i1.19 · Cited by 61
Cilia, R., Piatti, M., Cereda, E., Bolliri, C., Caronni, S., Ferri, V., Cassani, E., Bonvegna, S., Ferrarese, C., Zecchinelli, A. L., et al. (2021) · Journal of Parkinson's Disease · doi:10.3233/jpd-202297 · Cited by 51
“Moreover, Aho and colleagues (2019) did not replicate the findings reported by Minato and colleagues (2017) concerning the prognostic role of Bifidobac-terium [20, 21].”
InfluentialGastrointestinal disorders in Parkinson’s disease and other Lewy body diseases
Hirayama, M., Nishiwaki, H., Hamaguchi, T., & Ohno, K. (2023) · npj Parkinson s Disease · doi:10.1038/s41531-023-00511-2 · Cited by 66
“As stated above, the gut microbiota remains essentially unchanged over 2 years in both controls and PD 66,70,74 , and is independent of PD progression 74 .”
InfluentialSelf-citationGut Microbiota Approach—A New Strategy to Treat Parkinson’s Disease
Liu, J., Xu, F., Nie, Z., & Shao, L. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.570658 · Cited by 55
Rani, L., & Mondal, A. C. (2021) · Neuroscience Research · doi:10.1016/j.neures.2021.01.001 · Cited by 50
Menozzi, E., & Schapira, A. H. V. (2024) · CNS Drugs · doi:10.1007/s40263-024-01073-4 · Cited by 52
“Lower abundance of genera Bifidobacterium , Barnesiella or Roseburia , Completed [120] or predominance of the Firmicutes -dominated enterotype were associated with faster progression in PD [76, 124–126], whereas abundance of genus Prevotella was protective towards deterioration [125].”
BackgroundTargeting Gut Microbiota Dysbiosis: Potential Intervention Strategies for Neurological Disorders
Wu, W., Kong, Q., Tian, P., Zhai, Q., Wang, G., Liu, X., Zhao, J., Zhang, H., Lee, Y. K., & Chen, W. (2020) · Engineering · doi:10.1016/j.eng.2019.07.026 · Cited by 56
“positively associated with the worsening of PD in 2 years [98]”
BackgroundThe Microbiota-Gut-Brain Axis as a Key to Neuropsychiatric Disorders: A Mini Review
Stopińska, K., Radziwoń-Zaleska, M., & Domitrz, I. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10204640 · Cited by 51
Tsuji, H., Matsuda, K., & Nomoto, K. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01417 · Cited by 57
“A 2-year follow-up study by the same group recently revealed that lower counts of Bifidobacterium and Bacteroides fragilis in year 0 were associated with worsening on the Unified Parkinson’s Disease Rating Scale over the next 2 years, suggesting that changes in the intestinal microbiota are associated with the progres…”
BackgroundSelf-citationAppendectomy and risk of Parkinson's disease in two large prospective cohorts of men and women
Palacios, N., Hughes, K. C., Cereda, E., Schwarzschild, M. A., & Ascherio, A. (2018) · Movement Disorders · doi:10.1002/mds.109 · Cited by 46
Danilenko, V., Devyatkin, A., Marsova, M., Shibilova, M., Ilyasov, R. A., & Shmyrev, V. (2021) · Journal of Inflammation Research · doi:10.2147/jir.s333887 · Cited by 57
Association of Parkinson’s Disease With Microbes and Microbiological Therapy
Chen, Z.-J., Liang, C.-Y., Yang, L.-Q., Ren, S.-M., Xia, Y.-M., Cui, L., Li, X.-F., & Gao, B.-L. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.619354 · Cited by 45
Microbial treatment: the potential application for Parkinson’s disease
Fang, X. (2018) · Neurological Sciences · doi:10.1007/s10072-018-3641-6 · Cited by 49
Gastrointestinal Dysfunction in Parkinson’s Disease: Current and Potential Therapeutics
Han, M. N., Finkelstein, D. I., McQuade, R. M., & Diwakarla, S. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12020144 · Cited by 59
Age-Related Cognitive Decline, Focus on Microbiome: A Systematic Review and Meta-Analysis
Coradduzza, D., Sedda, S., Cruciani, S., Miglio, M. R. D., Ventura, C., Nivoli, A., & Maioli, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241813680 · Cited by 51
“The underlying facilitator for the relationship between cognition and the gut microbiome is the microbiome-gut-brain axis [52].”
BackgroundMethodInfluentialKrikorian, R., Kalt, W., McDonald, J. E., Shidler, M. D., Summer, S. S., & Stein, A. L. (2019) · Journal of Functional Foods · doi:10.1016/j.jff.2019.103667 · Cited by 47
Hasuike, Y., Endo, T., Koroyasu, M., Matsui, M., Mori, C., Yamadera, M., Fujimura, H., & Sakoda, S. (2020) · Medical Hypotheses · doi:10.1016/j.mehy.2019.109436 · Cited by 42
Friend or foe? Lactobacillus in the context of autoimmune disease
Fine, R. L., Mubiru, D. L., & Kriegel, M. A. (2020) · Advances in immunology · doi:10.1016/bs.ai.2020.02.002 · Cited by 46
The impact of device-assisted therapies on the gut microbiome in Parkinson’s disease
Lubomski, M., Xu, X., Holmes, A. J., Yang, J. Y. H., Sue, C. M., & Davis, R. L. (2021) · Journal of Neurology · doi:10.1007/s00415-021-10657-9 · Cited by 48
The impact of indigenous microbes on Parkinson's disease
Sampson, T. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.03.014 · Cited by 41
Metadata
- Authors
- Minato, T., Maeda, T., Fujisawa, Y., Tsuji, H., Nomoto, K., Ohno, K., & Hirayama, M.
- Affiliations
- Nagoya University (JP)
- Iwate Medical University (JP)
- Yakult Central Institute (JP)
- Corresponding author
- Ohno, Kinji
- Hirayama, Masaaki
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2017-11-01
- Volume
- 12
- Issue
- 11
- Pages
- e0187307
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC5665539
- OpenAlex
- W2766355490
- Cited by
- 248
- References
- 54
- Citations by year
- 2026: 11 · 2025: 9 · 2024: 27 · 2023: 29 · 2022: 40 · 2021: 42 · 2020: 37 · 2019: 33 · 2018: 19 · 2017: 1
- FWCI
- 17.13
- Type
- journal article
- Language
- en
- Update notices
- expression_of_concern (2023-01-11)
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Japan Society for the Promotion of Science (JP) (24500458, 15H04840)
- Japan Agency for Medical Research and Development (JP) (17gm1010002h0002)
- Smoking Research Foundation (JP)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- Parkinson's disease, gut dysbiosis, gut microbiota, disease progression, Unified Parkinson's Disease Rating Scale, Bifidobacterium, Bacteroides fragilis, Atopobium, delusions and hallucinations, motor symptoms, disease progression biomarkers
- MeSH terms
- Gastrointestinal Microbiome, Aged, Bacteroides fragilis, Bifidobacterium, Clostridium, Female, Follow-Up Studies, Humans, Male, Middle Aged, Parkinson Disease, Colony Count, Microbial, Disease Progression, Dysbiosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.